Literature DB >> 33615106

Renal Phosphate Handling: Independent Effects of Circulating FGF23, PTH, and Calcium.

Malachi J McKenna1,2,3, Rachel K Crowley1,2,3, Patrick J Twomey1,2, Mark T Kilbane1,2.   

Abstract

Excess fibroblast growth factor 23 (FGF23), excess PTH, and an increase in extracellular calcium cause hypophosphatemia by lowering the maximum renal phosphate reabsorption threshold (TmP/GFR). We recently reported two cases of X-linked hypophosphatemia (XLH) with severe tertiary hyperparathyroidism who had normalization of TmP/GFR upon being rendered hypoparathyroid following total parathyroidectomy, despite marked excess in both C-terminal FGF23 (cFGF23) and intact FGF23 (iFGF23). We explored the effects of FGF23, PTH, and calcium on TmP/GFR in a cross-sectional study (n = 74) across a spectrum of clinical cases with abnormalities in TmP/GFR, PTH, and FGF23. This comprised three groups: FGF23-dependent hypophosphatemia (n = 27), hypoparathyroidism (HOPT; n = 17), and chronic kidney disease (n = 30). Measurements included TmP/GFR, cFGF23, PTH, ionized calcium, vitamin D metabolites, and bone turnover markers. The combined effect of cFGF23, PTH, and ionized calcium on TmP/GFR was modeled using hierarchical multiple regression and was probed by moderation analysis with PROCESS. Modeling analysis showed independent effects on TmP/GFR by cFGF23, PTH, and ionized calcium in conjunction with a weak but significant effect of the interaction term for PTH and FGF23; probing showed that the effect was most prominent during PTH deficiency. Teriparatide 20 μg daily was self-administered for 28 days by one case of X-linked hypophosphatemia with hypoparathyroidism (XLH-HOPT) to assess the response of TmP/GFR, cFGF23, iFGF23, nephrogenous cyclic adenosine monophosphate (NcAMP), vitamin D metabolites, and bone turnover markers. After 28 days, TmP/GFR was lowered from 1.10 mmol/L to 0.48 mmol/L; this was accompanied by increases in NcAMP, ionized calcium, and bone turnover markers. In conclusion, the effect of FGF23 excess on TmP/GFR is altered by PTH such that the effect is ameliorated by hypoparathyroidism and the effect is augmented by hyperparathyroidism.
© 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.

Entities:  

Keywords:  FIBROBLAST GROWTH FACTOR 23; HYPERPARATHYROIDISM; HYPOPARATHYROIDISM; PARATHYROID HORMONE; X‐LINKED HYPOPHOSPHATEMIA

Year:  2020        PMID: 33615106      PMCID: PMC7872336          DOI: 10.1002/jbm4.10437

Source DB:  PubMed          Journal:  JBMR Plus        ISSN: 2473-4039


  3 in total

1.  Use of Teriparatide in Hyperphosphatemic Familial Tumor Calcinosis: Evaluating the Interaction Between FGF23 and PTH on the Phosphaturic Effect.

Authors:  Sthefanie Giovanna Pallone; Ilda Sizue Kunii; Renata Elen Costa da Silva; Marise Lazaretti-Castro
Journal:  Calcif Tissue Int       Date:  2022-03-25       Impact factor: 4.000

Review 2.  Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy.

Authors:  Mouhamed Nashawi; Mahmoud S Ahmed; Toka Amin; Mujahed Abualfoul; Robert Chilton
Journal:  World J Cardiol       Date:  2021-12-26

3.  High bone turnover and hyperparathyroidism after surgery for tumor-induced osteomalacia: A case series.

Authors:  Mark T Kilbane; Rachel Crowley; Eric Heffernan; Clare D'Arcy; Gary O'Toole; Patrick J Twomey; Malachi J McKenna
Journal:  Bone Rep       Date:  2021-10-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.